Alberto Ferlin1, Maria Santa Rocca2, Cinzia Vinanzi2, Marco Ghezzi2, Andrea Di Nisio2, Carlo Foresta2. 1. Department of Medicine, Unit of Andrology and Human Reproductive Medicine, University of Padova, Padova, Italy. Electronic address: alberto.ferlin@unipd.it. 2. Department of Medicine, Unit of Andrology and Human Reproductive Medicine, University of Padova, Padova, Italy.
Abstract
OBJECTIVE: To study the role of NR5A1 in cryptorchidism and male factor infertility. Mutations in NR5A1 have been initially associated with primary adrenal insufficiency and 46,XY gonadal dysgenesis and more recently with less severe phenotypes, including preliminary descriptions in severe forms of male factor infertility. Far less clear is the possible involvement of NR5A1 mutations in cryptorchidism. DESIGN: Retrospective cross-sectional cohort study and functional analysis of mutant proteins. SETTING: University department. PATIENT(S): Nine hundred fifty-nine subjects, including children with cryptorchidism and adults with different semen phenotypes associated or not associated with a history of cryptorchidism. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Mutation screening of NR5A1 by sequencing all exons. Functional analysis of mutant proteins by transactivation assays of CYP11A1 and CYP17A1 promoters. RESULT(S): We identified seven undescribed and one previously described missense mutation in subjects with severe spermatogenic impairment, without (4/236, 1.7%) and with (3/85, 3.5%) a history of cryptorchidism. Newborns with cryptorchidism carry NR5A1 mutations at low frequency (0.7%), whereas no mutations were found in milder forms of infertility and normozoospermia, irrespective of the presence of cryptorchidism. The mutant proteins showed impaired transactivation of gonadal promoters. A single nucleotide polymorphism (rs1110061; c.437 G→C; p.Gly146Ala) was also associated with more severe forms of spermatogenic impairment with cryptorchidism. CONCLUSION(S): This study, combined with what is already known about NR5A1-associated phenotypes, suggests considering mutations in this gene as a novel genetic cause of more severe forms of male factor infertility, especially when associated with a history of cryptorchidism.
OBJECTIVE: To study the role of NR5A1 in cryptorchidism and male factor infertility. Mutations in NR5A1 have been initially associated with primary adrenal insufficiency and 46,XY gonadal dysgenesis and more recently with less severe phenotypes, including preliminary descriptions in severe forms of male factor infertility. Far less clear is the possible involvement of NR5A1 mutations in cryptorchidism. DESIGN: Retrospective cross-sectional cohort study and functional analysis of mutant proteins. SETTING: University department. PATIENT(S): Nine hundred fifty-nine subjects, including children with cryptorchidism and adults with different semen phenotypes associated or not associated with a history of cryptorchidism. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Mutation screening of NR5A1 by sequencing all exons. Functional analysis of mutant proteins by transactivation assays of CYP11A1 and CYP17A1 promoters. RESULT(S): We identified seven undescribed and one previously described missense mutation in subjects with severe spermatogenic impairment, without (4/236, 1.7%) and with (3/85, 3.5%) a history of cryptorchidism. Newborns with cryptorchidism carry NR5A1 mutations at low frequency (0.7%), whereas no mutations were found in milder forms of infertility and normozoospermia, irrespective of the presence of cryptorchidism. The mutant proteins showed impaired transactivation of gonadal promoters. A single nucleotide polymorphism (rs1110061; c.437 G→C; p.Gly146Ala) was also associated with more severe forms of spermatogenic impairment with cryptorchidism. CONCLUSION(S): This study, combined with what is already known about NR5A1-associated phenotypes, suggests considering mutations in this gene as a novel genetic cause of more severe forms of male factor infertility, especially when associated with a history of cryptorchidism.
Authors: Jason K Gurney; Katherine A McGlynn; James Stanley; Tony Merriman; Virginia Signal; Caroline Shaw; Richard Edwards; Lorenzo Richiardi; John Hutson; Diana Sarfati Journal: Nat Rev Urol Date: 2017-06-27 Impact factor: 14.432
Authors: Jenifer P Suntharalingham; Federica Buonocore; Andrew J Duncan; John C Achermann Journal: Best Pract Res Clin Endocrinol Metab Date: 2015-07-14 Impact factor: 4.690
Authors: Samantha A M Young; Haruhiko Miyata; Yuhkoh Satouh; Hirotaka Kato; Kaori Nozawa; Ayako Isotani; R John Aitken; Mark A Baker; Masahito Ikawa Journal: Int J Mol Sci Date: 2015-10-16 Impact factor: 5.923
Authors: Gorjana Robevska; Jocelyn A van den Bergen; Thomas Ohnesorg; Stefanie Eggers; Chloe Hanna; Remko Hersmus; Elizabeth M Thompson; Anne Baxendale; Charles F Verge; Antony R Lafferty; Nanis S Marzuki; Ardy Santosa; Nurin A Listyasari; Stefan Riedl; Garry Warne; Leendert Looijenga; Sultana Faradz; Katie L Ayers; Andrew H Sinclair Journal: Hum Mutat Date: 2017-11-02 Impact factor: 4.878